Claims for Patent: 5,714,383

Summary for Patent: 5,714,383

Title:	Method and reagent for treating chronic myelogenous leukemia
Abstract:	An enzymatic RNA molecule which cleaves mRNA associated with development or maintenance of CML.
Inventor(s):	Thompson; James D. (Boulder, CO)
Assignee:	Ribozyme Pharmaceuticals, Inc. (Boulder, CO)
Application Number:	08/363,233
Patent Claims:	1. An enzymatic nucleic acid molecule which specifically cleaves mRNA encoded by a bcr/abl gene, and wherein said nucleic acid binds to the bcr portion of said bcr/abl mRNA. 2. An enzymatic nucleic acid molecule which specifically cleaves mRNA encoded by a bcr/abl gene, and wherein said nucleic acid binds to the abl portion of said bcr/abl mRNA. 3. An enzymatic nucleic acid molecule which specifically cleaves mRNA encoded by a bcr/abl gene; wherein said nucleic acid comprises two target binding arms, one of said binding arms is complementary to the bcr portion and second said arm is complementary to the abl portion of said bcr/abl mRNA; and wherein said nucleic acid cleaves said mRNA immediately after sequence HUH, wherein H represents adenosine, uridine, or cytidine, and U represents uridine. 4. The enzymatic nucleic acid molecule of claim 1, wherein said mRNA is identified as any of SEQ ID NOS. 1-9, and wherein said nucleic acid is in a hepatitis delta virus configuration. 5. The enzymatic nucleic acid molecule of any of claims 1, 2, or 3, wherein said nucleic acid molecule is in a hammerhead motif. 6. The enzymatic nucleic acid molecule of any of claims 1, or 2, wherein said nucleic acid molecule is in a hairpin, hepatitis Delta virus, group I intron, Neurospora VS RNA or RNaseP RNA motif. 7. The enzymatic nucleic acid of any of claims 1, 2, or 3, wherein said nucleic acid comprises between 5 and 23 bases complementary to said mRNA. 8. The enzymatic nucleic acid of any of claims 1, 2, or 3, wherein said nucleic acid comprises between 10 and 18 bases complementary to said mRNA. 9. The enzymatic nucleic acid molecule of claim 5, wherein said nucleic acid comprises a sequence defined as any of SEQ ID NOS. 26-31. 10. The enzymatic nucleic acid of any of claims 1, 2, or 3, wherein said bcr/abl gene is formed by a b2-a2 chromosomal translocation. 11. The enzymatic nucleic acid of any of claims 1, 2, or 3, wherein said bcr/abl gene is formed by a b3-a2 chromosomal translocation. 12. The enzymatic nucleic acid molecule of claim 2, wherein said mRNA is defined as any of SEQ ID NOS. 10-19, and wherein said nucleic acid is in a hepatitis delta virus configuration. 13. The enzymatic nucleic acid molecule of claim 1, wherein said mRNA is defined as any of SEQ ID NOS. 1-3, and 5-9, and wherein said nucleic acid is in a hammerhead configuration. 14. The enzymatic nucleic acid molecule of claim 2, wherein said mRNA is defined as any of SEQ ID NOS. 10, 11, and 14-18, and wherein said nucleic acid is in a hammerhead configuration. 15. The enzymatic nucleic acid molecule of claim 3, wherein said mRNA is defined as any of SEQ ID NOS. 20-25, and wherein said nucleic acid is in a hammerhead configuration. 16. The enzymatic nucleic acid molecule of claim 5, wherein said nucleic acid comprises a stem II region, and wherein the length of said stem II is greater than or equal to 2 base pairs. 17. The enzymatic nucleic acid of claim 6, wherein said hairpin comprises a stem IV region, and wherein the length of said stem IV is greater than or equal to 2 base pairs. 18. The enzymatic nucleic acid of any of claims 4, 1, 2, 3 or 12-15, wherein said nucleic acid comprises at least one sugar modification. 19. The enzymatic nucleic acid of any of claims 4, 1, 2, 3 or 12-15, wherein said nucleic acid comprises at least one base modification. 20. The enzymatic nucleic acid of any of claims 4, 1, 2, 3 or 12-15, wherein said nucleic acid comprises at least one phosphate modification. 21. The enzymatic nucleic acid of any of claims 4, 1, 2, 3 or 12-15, wherein said nucleic acid comprises at least two sugar modifications, wherein one said modification is a 2'-O-methyl and the other said modification is a 2'-deoxy-2'-amino. 22. The enzymatic nucleic acid of any of claims 4, 1, 2, 3 or 12-15, wherein said nucleic acid comprises at least two sugar modifications, wherein one said modification is a 2'-O-methyl and the other said modification is a 2'-C-allyl. 23. The enzymatic nucleic acid of claim 20, wherein said phosphate modification is a phosphorothioate. 24. A mammalian cell comprising an enzymatic nucleic acid molecule of any of claims 4, 1, 2, 3 or 12-15. 25. The cell of claim 7, wherein said cell is a human cell. 26. An expression vector including nucleic acid encoding the enzymatic nucleic acid molecule or multiple enzymatic nucleic molecules of any of claims 4, 1, 2, 3 or 12-15 in a manner which allows expression and delivery of that enzymatic nucleic acid molecule within a mammalian cell.

Details for Patent 5,714,383

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2015-02-03
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2015-02-03
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2015-02-03